The use of antiarrhythmic drug treatment and modulated kinesitherapy for primary prevention of atrial fibrillation in patients with metabolic syndrome

Olesin A. I., Konstantinova I. V., Ivanov V. S.

ABSTRACT

Objective. To assess the effectiveness antiarrhythmic drug treatment (ADT) and modulated kinesitherapy (MK) for primary prevention of atrial fibrillation (AF) in patients with metabolic syndrome (MS) and premature atrial contractions (PACs).

Materials and methods. The study included 426 patients with MS and PACs aged from 58 to 72 years (average age — 66.4±0.7 years) with high risk of primary AF development (during one-year follow-up after the inclusion into the study). ADT with I–III antiarrhythmic agents was used for the primary AF prevention (excluding amiodarone) in 149 (34.97%) patients, MK — in 121 (28.40%), and blood pressure (BP), blood glucose and lipids level correction — in the rest. The primary endpoint after one-year follow-up was: the maintenance of sinus rhythm or AF registration.

Results. The rate of paroxysmal and persistent AF in patients prescribed with ADT and MK for the primary prevention of AF with MS and premature atrial contractions within one year after the first examination was 26.45% and 31.54%, respectively. The use of ADT and MK in patients with MS reduced the frequency of AF by 3 times on average compared with the correction of potentially modifiable MS risk factors.

Conclusion. The implementation of ADT with I-III antiarrhythmic agents as well as MK for the AF primary prevention in patients with MK with PACs and the risk of AF development one year after the first examination allowed to reduce the frequency of this arrythmia by 3 times compared with regular BP, blood glucose and lipids level correction.

Keywords: metabolic syndrome, primary atrial fibrillation prevention, antiarrhythmic therapy, modulated kinesitherapy.

For citation:

Olesin A. I., Konstantinova I. V., Ivanov V. S. The use of antiarrhythmic drug treatment and modulated kinesitherapy for primary prevention of atrial fibrillation in patients with metabolic syndrome. International Heart and Vascular Disease Journal. 2022. 10 (34): 4-10. DOI 10.24412/2311-1623-2022-34-5-13